Checkpoint Inhibitors In Hematologic Malignancies
Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses Checkpoint Inhibitors In Hematologic Malignancies...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
The Role Of Checkpoint Inhibitors In Treatment Of MM
Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, Discusses The Role Of Checkpoint Inhibitors In Treatment Of MM. At The 60th ASH Annual Mee...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Proteasome Inhibitors In The Treatment Of MM
Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses Proteasome Inhibitors In The Treatment Of MM. At The 60th ASH Annual Meeting on ...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
The Clinical Study Investigating Mosunetuzumab
Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses The Clinical Study Investigating Mosunetuzumab. At The 60th ASH A...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL
Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Results Of The AUGMENT Study In Relapsed/Refractory Indolent NHL. At The...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Improvements Made In The Delivery Of CAR-T Therapies
Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, Discusses Improvements Made In The Delivery Of CAR-T Therapies. At The 60th ASH An...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Outcomes Of The TOURMALINE-MM3 Study
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Outcomes Of The TOURMALINE-MM3 Study. At The 60th ASH Annual Meet...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Most Exciting Studies In Lymphoma
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses Most Exciting Studies In Lymphoma. At The ...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Improvements In The Treatment Of CTCL
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Improvements In The Treatment Of CTCL. At The 60th ASH Annual Meeting on Dec 1, ...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
The Rationale For Genetically Profiling AML Patients
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses The Rationale For Genetically Profiling AML Patients. At The 60th...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
The Current Standard Of Care For The Frontline Treatment Of PTCL
Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Gttingen, discusses The Current Standard Of Care For The Front...
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
What Differeniates Brentuximab Vedotin From Other Treatment Options
Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Gttingen, discusses What Differeniates Brentuximab Vedotin Fro...
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Rituximab Biosimilars In Follicular Lymphoma
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses Rituximab Biosimilars In Follicular Lymphoma. A...
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
Outcomes Of The ECHELON-2 Study
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Outcomes Of The ECHELON-2 Study. At The 60th ASH Annual Meeting on Dec 1, 2018.
Author: obr
Added: 01/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 14, 2019 Category: Cancer & Oncology Source Type: podcasts
